Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959]

Vaccine

Volumn 25, Issue 15, 2007, Pages 2766-2767

  Zink, Thomas K ^a  

^a Emergent Biosolutions   (United States)

Author keywords

Anthrax; Biothrax; Immunogenicity; Reactogenicity; Recombinant protective antigen; Safety; Vaccine

Indexed keywords

ANTHRAX VACCINE; RECOMBINANT VACCINE;

ANTHRAX; BIOLOGICAL WARFARE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LETTER; METHODOLOGY; PRIORITY JOURNAL;

ANTHRAX VACCINES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; VACCINES, SYNTHETIC;

EID: 33947173140     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.040     Document Type: Letter

References (5)

1. Gorse, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rpa102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 33-34 (2006) 5950-5959
2. DHHS-FDA. 51058. Federal register, vol. 50, no. 240. Friday, December 13, 1985. Part II. In FDA, 1985.
3. DHHS-FDA. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; FINal order, federal register 2005; 70:75180-198 (December 19, 2005). ("Final Order").
4. Sever J.L., Brenner A.L., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS). Pharmacoepidemiol Drug Saf 13 12 (2004) 825-840
5. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 9-10 (2002) 1412-1420